Basic Information
LncRNA/CircRNA Name | PSLNR |
Synonyms | NA |
Region | NA |
Ensemble | NA |
Refseq | NA |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | apoptosis | Drug | ||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | Prostate cancer |
ICD-0-3 | C61.9 |
Methods | qPCR, Western blot, RNAi |
Sample | LNCaP cells, 22RV1, DU145, PC-3, and WPMY-1, tumor tissues and three adjacent normal tissues |
Expression Pattern | down-regulated |
Function Description | We reported a novel androgen-reduced prostate-specific lncRNA, PSLNR, that inhibited PCa progression via the p53-dependent pathway. By analyzing the NOCODE data set, we reported that PSLNR was specifically expressed in the prostate, suggesting the potential of PSLNR as a biomarker for PCa treatment. The AR pathway was also confirmed to be an upstream regulation signaling pathway of PSLNR by transcriptionally regulating its expression in androgen-dependent PCa cells. PSLNR also significantly inhibited PCa proliferation by inducing cell apoptosis in a p53-dependent manner. Thus, PSLNR may be a candidate diagnosis and therapeutic target for PCa. |
Pubmed ID | 31269242 |
Year | 2019 |
Title | A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway |
External Links
Links for PSLNR | GenBank HGNC NONCODE |
Links for Prostate cancer | OMIM COSMIC |